In the case of biological drugs such as the monoclonal cytokine inhibitors, Hanna and Fragogiannis [66] have suggested that a promising role could be played by the inhibitors of IL-1 and IL-6, canakinumab and tocilizumab, while the observations acquired in humans failed to prove benefits from treatments with TNF-alpha inhibitors in heart failure [66]. The gene discussed is IL1B; the disease is heart failure.